Texas

Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.

EYSUVIS is the first FDA-approved ocular corticosteroid for the treatment of dry eye disease. Know more about how it got approval and the complete development timeline here.

Molecular science company Caris Life Sciences secured $310 million in growth capital that will be used to expand its presence in precision medicine in oncology.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

At a recent Demy-Colton Virtual Salon, Michael Gaito, head of healthcare investment banking at J.P. Morgan, discussed the strength of capital raises despite COVID-19 and the resilient state of the biotech sector in the run-up to the Presidential election in November and the virtual J.P. Morgan Healthcare Conference (and the virtual Biotech Showcase) in January, with Dennis Purcell, founder of Aisling Capital LLC.

Starting with $30 million in seed financing in April, Taysha sprinted through a $95 million Series B in August and rounded the corner this Thursday to bring in $157 million for its IPO.

The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.